The Use of Medical Cannabis for Treatment of Chronic Pain: An Integrative Research Review

Brittany Van Dover* and Maria Rosario Sim*
SUNY Downstate Medical Center College of Nursing, USA

Abstract

Chronic pain is a common problem that affects patients in the United States (US), Canada, and Australia. The treatment of chronic pain includes the use of opioids, however, with the growing epidemic, alternative options are being sought. The use of medical cannabis (marijuana) as treatment for chronic pain is increasing in popularity as an alternative for opioids. The aim of this Integrative Research Review (IRR) was to explore the efficacy of medical cannabis for chronic non-cancer pain treatment. PubMed and Google Scholar were used for literature search engines. Keywords used to retrieve articles were efficacy, medical cannabis, medical marijuana, non-cancer chronic pain, neuropathic pain, opioids, substitution, and treatment. Inclusion criteria were articles published in the US, Canada and Australia, and those written in the English language. Exclusion criteria were articles prior to 2010 and subjects less than 18 years of age. Ten articles were included in the IRR: four systematic reviews of randomized controlled trials, one randomized controlled trial, two cross-sectional observational studies, one secondary data analysis, one prospective cohort study, and one historical cohort study. Pain was measured using the Visual Analog Scale (VAS), Descriptor Differential Scale (DDS), numerical rating scale, Brief Pain Inventory (BPI) and/or quality of life in these studies. Most results showed that medical cannabis was an effective treatment for the reduction of chronic pain and increased quality of life, with the exception of the Australian prospective cohort study. Adverse effects of cannabis included short-term neurocognitive decline and worsening of psychiatric illness. Cannabis was also associated with a reduction or cessation of opioid use in the US and Canadian articles, prescribing patterns and spending in medicare enrollees in states where medical cannabis laws were implemented. Findings suggest that clinical practice should include substituting medical cannabis for opioids in the long-term management of chronic pain in countries with medical cannabis laws.

Keywords: Efficacy; Medical cannabis; Medical marijuana; Chronic pain; Non-cancer; Neuropathic pain; Opioids; Substitution

Introduction

Chronic pain is a worldwide issue that can be devastating to patients if not managed appropriately. In 2016, an estimated 20.4% (50 million) of United States adults suffered from chronic pain [1,2]. Opioids have been the drug of choice for several years in the treatment of chronic pain. The overuse of opioids has led to the current opioid epidemic. As a result, many patients are using opioids to treat chronic pain, which can lead to problems such as addiction, overdose and diversion. Meanwhile, opioids kill an average of 115 Americans a day [3]. Therefore, the use of medical cannabis needs to be examined further for management of chronic pain.

Chronic pain affects quality of life and productivity, and “may be accompanied by difficulty moving around, disturbed sleep, anxiety, depression and other problems” [4]. Chronic pain has also become a costly burden for the United States healthcare system. The annual economic cost of chronic pain, including both treatment and lost productivity has been estimated at up to $635 billion [4]. It is imperative that we find effective long-term pain management treatment to prevent further complications in the healthcare system and the economic consequences.

The purpose of this integrative review was to examine the use of medical cannabis as a treatment option for chronic non-cancer pain. The goal of this review was to determine how medical cannabis was used in the treatment of chronic pain in patients who were 18 years and older in the last eight years from 2010 to 2018.
Background

Medical cannabis has been explored as a therapeutic option for pain management throughout the United States (US) and Canada. In the US, federal regulations limit researchers to conduct rigorous studies on medical cannabis due to its schedule I status. On the other hand, in Canada, medical cannabis is legal both for medical and recreational purposes. Since cannabis is classified in the same category as heroin in the US at the federal level with no currently accepted medical use and high potential for abuse, it hinders researchers' ability to explore its treatment efficacy and safety [5]. However, at the state level, cannabis is legalized for medicinal use in 31 states [6]. Therefore, studies can be conducted in certain states due to its legality. Additionally, medical cannabis use was decriminalized in Australia on October 20, 2016 [7]. Although, randomization of a sample may not be feasible since statewide cannabis programs involve patient self-enrollment into a medical cannabis program. With these barriers to research studies, medical cannabis access to patients and physicians is limited when exploring it as a safe alternative to opioids.

The focus of this review is on the US and Canada due to the overwhelming use of opioids than anywhere else in the world [8]. In this review, it illustrated the following:

The United States and Canada are in the midst of an epidemic of the use, misuse and overdose of opioids, and deaths related to overdose. This is the direct result of overstatement of the benefits and understatement of the risks of using opioids by advocates and pharmaceutical companies. Massive amounts of prescription opioids entered the community and were often diverted and misused. Most other parts of the world achieve comparable pain relief using fewer opioids [8].

Therefore, it is clear that opioid use in the US and Canada needs to be curtailed and better options should be pursued.

In 2017, almost 58 opioid prescriptions were written for every 100 Americans [3]. Perhaps providers feel more comfortable prescribing opioids because of their familiarity with them, but this is a substantial amount of opioids considering that several Americans die of opioid overdose each day [3]. What is more, opioids are addicting and produce feelings of happiness, "the more people take them, the more they crave them" [4]. Opioid addiction inevitably develops after months of exposure and carries a high risk of relapse for years without proper treatment [9]. Opioid addiction leads to increased doses, which consequently increases the risk of overdose. Unfortunately, the over-prescribing of opioids for chronic pain management continues with these known consequences.

There is growing research that supports the use of medical cannabis for chronic back pain or hip or knee osteoarthritis pain, neuropathic pain, fibromyalgia and other diagnoses [11-12]. Such study was done, which found that cannabis is a safe, well tolerated, and effective option to help patients cope with malignancy related symptoms [13]. There has also been evidence suggesting a synergistic effect of cannabis combined with the use of opioids [14]. What is more, opioids have the fatal side effect of respiratory depression, which cannabis does not. However, cannabis does have psychoactive effects and neurocognitive decline, which have been linked to increased incidences of motor vehicle accidents, which can be deadly [15]. Interestingly, in the US, there is mounting evidence that demonstrates the states with medical cannabis laws had a 25% lower mean annual opioid overdose mortality rate compared to states without such laws [16]. Similarly, implementation of state medical cannabis laws was associated with a 5.88% reduction in Medicaid-covered prescriptions for opioids (95% confidence interval) [17].

The medicinal components of cannabis are THC and Cannabidiol (CBD). THC causes the "high" or psychoactive effects, while CBD is not intoxicating at typical doses [18]. THC also has higher risk for adverse events. There are many forms of CBD available over the counter at health food retailers and pharmacies; however, they lack FDA approval [18].

Theoretical Framework

Betty Neuman’s Systems Model was used as a theoretical framework for this integrative review [19]. The Neuman’s Systems Model posits the idea of holistic orientation to wellness, which includes five variables of the person: physiological, psychological, sociocultural, developmental and spiritual [19]. The three variables pertinent to this review were physiological, psychological, and developmental. Chronic pain is a physiological variable which affects a patients overall wellbeing. Those suffering from untreated chronic pain cannot be in a stable state. Moreover, chronic pain may affect one’s psychological wellbeing. It may negatively impact a person’s emotions and ultimately lead to depression. Lastly, the developmental variable, such as one’s age can influence his or her response to treatment and outcomes. Chronic pain becomes more prominent as one grows older and treatment remedies can affect one differently based on his or her age. For example, the very young and the elderly are considered vulnerable populations since they respond differently to medical cannabis than someone between the ages of eighteen and sixty-five years. Additionally, there are certain groups in which medical cannabis may not be appropriate including adolescents, pregnant women, and people with psychosis [20].

Methods

The databases used for the literature search were PubMed and Google Scholar. Keywords used to retrieve articles included: efficacy, medical, cannabis, cannabinoids, marijuana, chronic pain, neuropathic pain, opioids, substitution, and treatment. Inclusion criteria included articles that were published in the US, Canada, and Australia, and those written in the English language from 2010 to 2018. Reviews outside of the US, Canada, and Australia, such as in Europe were excluded due to differences in the cannabis laws and lower use of opioids. Exclusion criteria included articles prior to 2010 and subjects less than eighteen years of age.

PubMed database

The PubMed database resulted in fifty-five articles related to the research question. From the fifty-five articles, forty abstracts were reviewed to determine if they were significant to answer the research question. From these abstracts, only six articles were isolated for full text review because they met the inclusion criteria for the study.

Google scholar database

The Google Scholar database resulted in sixty-five results. Keywords including cannabis, marijuana and chronic pain were used to search for article titles that related to the research question. Forty-five abstracts were reviewed to determine eligibility for inclusion. Only three articles were relevant to the research question.

Evaluation table

Appendix A is the evaluation table (Table 1) of all articles included
Table 1: A summary of reviewed studies.

<table>
<thead>
<tr>
<th>Citation: Author(s), date of publication and Title</th>
<th>Design method</th>
<th>Sample/ setting</th>
<th>Major variables studied and their definition</th>
<th>Measurement of major variables</th>
<th>Data analysis</th>
<th>Study Findings</th>
<th>Appraisal of worth to practice: Level of evidence, study strength and weakness*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Andreae MH et al. [12]. Inhaled Cannabis for Chronic Neuropathic Pain: A Meta-Analysis of Individual Patient Data.</td>
<td>Systematic review of RCT's and Meta-analysis.</td>
<td>5 RCT's n=178 w/chronic neuropathic pain.</td>
<td>Control: cigarettes w/THC removed. Intervention: cannabis cigarettes with THC.</td>
<td>Change in pain intensity using Visual Analog Scale (VAS) or Descriptor Differential Scale (DDS).</td>
<td>Results were pooled using Bayesian pooled effect w/95% CI. The Bayes factor is 332 w/ a posterior probability effect of 99.7%.</td>
<td>Inhaled cannabis for chronic neuropathic pain resulted in short-term reductions in pain for about 1 in 5 patients.</td>
<td>Level I evidence. Strength: RCT with control and experimental group. Consistency of results across different populations created generalizability of results. Weakness: Small sample size, small number of studies, short study duration, and inability to blind patients due to psychoactive effects of cannabis.</td>
</tr>
<tr>
<td>Deshpande A et al. [14]. Efficacy and Adverse effects of medical marijuana for chronic non-cancer pain: Systematic review of randomized controlled trials.</td>
<td>Systematic Review of RCT's.</td>
<td>6 RCT's n=226 adults (ages 45 to 50 years) w/chronic neuropathic pain were randomized, w/189 adults specifically having chronic neuropathic pain.</td>
<td>Control: cigarettes containing 0% delta-9-THC that were identical to cannabis cigarettes. Intervention: cigarettes containing delta-9-THC w/ varying potencies ranging from 1% to 9.4%.</td>
<td>Pain intensity measured by Visual Analog Scale (VAS) or numeric rating scale.</td>
<td>Data could not be pooled due to heterogeneity in delta-9-THC potency.</td>
<td>The use of medical cannabis for chronic neuropathic pain was associated with a reduction in pain and short-term neurocognitive adverse effects.</td>
<td>Level I evidence. Strength: RCT with control and experimental group. Weakness: small sample size, short study duration, and variability in delta-9-THC potencies.</td>
</tr>
<tr>
<td>Bowen LL et al. [22]. Therapeutic Benefit of Smoked Cannabis for Intractable Anorexia Due to HIV/AIDS: A Systematic Review of Randomized Placebo-Controlled Studies.</td>
<td>Systematic Review of RCT's.</td>
<td>7 RCT's n=208 patients of which 170 were experienced cannabis smokers.</td>
<td>Control: placebo cigarettes w/0% THC. Intervention: Cigarettes with THC ranging from 1% to 9.4%.</td>
<td>Pain intensity rating measured via VAS or Descriptor Differential Scale (DDS). Caloric intake, change in spasticity and intraocular pressure were also measured.</td>
<td>Data could not be pooled due to heterogeneity in delta-9-THC potency.</td>
<td>Smoked cannabis showed subjective improvements in pain. It also had therapeutic benefits such as decreased pain and spasticity in multiple sclerosis, and increased appetite and calories in HIV associated anorexia. Additionally, smoked cannabis decreased intraocular pressure in patients with glaucoma for a short duration.</td>
<td>Level I evidence. Strength: RCT with control and experimental group. Weakness: Small sample size, short study duration, and inability to blind patients due to psychoactive effects of cannabis. Also, patients with Depression were excluded, which limits generalizability.</td>
</tr>
<tr>
<td>Hill K.P [23]. Medical Marijuana for Treatment of Chronic Pain and Other Medical and Psychiatric Problems: A Clinical Review.</td>
<td>Systematic Review of RCT's.</td>
<td>28 RCT's of cannabinoids for indications other than FDA-approved cannabinoids (dronabinol and nabilone), 6 trials n=325 patients with chronic pain, 6 trials n=938 with neuropathic pain, and 12 trials n=1600 related to Multiple Sclerosis.</td>
<td>Control: cannabis placebo containing 0% THC. Intervention: Cannabis w/THC.</td>
<td>VAS, subjective pain intensity change, mean pain severity, change in the following: spasticity, muscle stiffness, incontinence episodes, sleep disturbance, tremors, cognition, dyskinesia, and activity index.</td>
<td>Data could not be pooled due to heterogeneity in delta-9-THC potency.</td>
<td>Medical cannabis can treat chronic pain, neuropathic pain, and spasticity associated with Multiple Sclerosis. There are adverse effects of Cannabis such as addiction and worsening of psychiatric illness.</td>
<td>Level I evidence. Strength: RCT with control and experimental group. Weakness: Small sample sizes in the studies and variability in THC doses.</td>
</tr>
<tr>
<td>Study</td>
<td>Design</td>
<td>Participant</td>
<td>Outcome Measure</td>
<td>Data Collection Method</td>
<td>Type</td>
<td>Findings</td>
<td>Strength</td>
</tr>
<tr>
<td>---------------------------------------------------------------------</td>
<td>-------------------------------</td>
<td>--------------------------------------------</td>
<td>---------------------------------------------------------------------------------</td>
<td>------------------------</td>
<td>----------------------------------------------------------------------</td>
<td>--------------------------------------------------------------------------------------------------</td>
<td>-----------------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>Krebs EE et al. [10]. Effect of Opioid vs. Nonopioid Medications on Pain-Related Function in Patients With Chronic Back Pain or Hip or Knee Osteoarthritis Pain: The SPACE Trial</td>
<td>Randomized Controlled Trial.</td>
<td>N=240 patients recruited from Veterans Affairs who had moderate to severe chronic back or hip or knee osteoarthritis.</td>
<td>Primary outcome=pain related function over 12 months (Brief pain inventory interference [BPI] scale)</td>
<td>Statistical significance threshold was P less than 0.05.</td>
<td>Multivariate analysis was used to identify the association of medical cannabis use with lower odds of opioid use (0.57; 95% confidence interval: 0.38-0.87).</td>
<td>Pain intensity was significantly better in non-opioids than opioids over a 12 month period (p=0.03).</td>
<td>Level II evidence.</td>
</tr>
<tr>
<td>Sohler NL et al. [27]. Cannabis use is associated with lower odds of prescription opioid analgesic use among HIV-infected individuals with chronic pain</td>
<td>Secondary Data Analysis.</td>
<td>N=459 HIV-infected patients with chronic pain, a convenience population from Bronx HIV clinics and drug treatment programs.</td>
<td>Cannabis use, alcohol, and illicit drug use patients prescribed opioids</td>
<td>Multivariate analysis was used to find the associate of medical cannabis use with lower odds of opioid use (0.57; 95% confidence interval: 0.38-0.87).</td>
<td>Multivariate analysis was used to find the associate of medical cannabis use with decreased use of opioid analgesics in multivariate analysis.</td>
<td>Cannabis use was the only substance associated with decreased use of opioid analgesics in multivariate analysis.</td>
<td>Level III evidence.</td>
</tr>
<tr>
<td>Boehnke KF et al. [16] (2016). Medical Cannabis Use is Associated with Decreased Opiate Medication Use in a Retrospective Cross-Sectional Survey of Patients With Chronic Pain</td>
<td>Cross-sectional observational study.</td>
<td>N=185, medical cannabis patients at a dispensary in Michigan.</td>
<td>Effects of cannabis on opioid use: measured the change in opioid use when using cannabis for chronic pain. Effects of cannabis on number of medication classes used: measured the change in medications when using cannabis for chronic pain. Effect of cannabis on side effects: measured the change in side effects after initiation of cannabis.</td>
<td>Variables measured via 46 question survey.</td>
<td>Descriptive statistics was used to limit analysis to completed questionnaires. Student t-tests were used to examine cannabis use and medication classes. Paired t-tests were used to study changes before and after cannabis use.</td>
<td>Medical cannabis use is associated with a decrease in opioids by 64%. Patients were essentially substituting opioids for other medication classes. Subjects found fewer side effects with medical cannabis.</td>
<td>Level III evidence.</td>
</tr>
<tr>
<td>Reiman A et al. [26]. Cannabis as a substitute for opioid-based pain medication: patient self-report.</td>
<td>Cross-sectional observational study.</td>
<td>N=2897 medical cannabis patients in the state of California.</td>
<td>Cannabis, opioid, and non-opioid based medications.</td>
<td>Measured via email survey by indicating the following: &quot;strongly agree&quot;, &quot;agree&quot;, &quot;disagree&quot;, or &quot;strongly disagree&quot;.</td>
<td>N/A</td>
<td>97% of patients who use cannabis &quot;strongly agreed/agreed&quot; that they are able to decrease opioids when using cannabis.</td>
<td>Level III evidence.</td>
</tr>
</tbody>
</table>
**Results**

Initial electronic database search yielded 120 articles. Ten articles that fit the inclusion and exclusion criteria were included for review. Articles included in the review were four systematic reviews, one randomized controlled trial, and two cross sectional observational studies, one secondary data analysis, one prospective cohort study, and one historical cohort study. The Rating system for the Hierarchy of Evidence for Intervention and Treatment Questions by Melnyk et al. [21] was used to evaluate the level of evidence for each study. The articles consisted of four level I evidence (systematic reviews), one level II evidence (randomized controlled trial), three level III evidence (two cross sectional observational studies, and one secondary data analysis), and two level IV (cohort studies).

**Discussion**

This IRR supports medical cannabis as a therapeutic alternative to opioids with sufficient evidence. In nine studies, medical cannabis was evaluated to test its effects on pain intensity. In the four systematic reviews of RCT’s, the use of medical cannabis containing THC, the psychoactive ingredient in cannabis demonstrated reductions in pain for all studies. However, there were about five RCT’s that were used in all four systematic reviews, which clearly lead to identical results. Additionally, it was discovered that medical cannabis had therapeutic benefits such as decreased spasticity in Multiple Sclerosis and increased appetite and caloric intake in HIV associated anorexia [22]. Cannabis also decreased intraocular pressure in glaucoma for a short duration. Adverse effects such as neurocognitive decline were consistent in all studies, however. Similarly, decreased spasticity was also evident in the findings [23]. Other adverse events found included

<table>
<thead>
<tr>
<th>Study</th>
<th>Participants</th>
<th>Study Design</th>
<th>Sample</th>
<th>Data Collection</th>
<th>Level of Evidence</th>
<th>Strength</th>
<th>Weakness</th>
</tr>
</thead>
<tbody>
<tr>
<td>Vigil JM et al. [28]</td>
<td>Sample of 37 chronic pain patients (mean age 54 years old, 54% male, 86% back pain) who use opioids and were enrolled New Mexico’s Medical Cannabis Program (MCP).</td>
<td>Historical Cohort Study</td>
<td>Survey questions measured pain levels prior to and after Medical Cannabis Program (MCP).</td>
<td>Logistic regression model was used to analyze the first 3 months and the last three months of observation.</td>
<td>Multinomial logistic regression models used to compare less frequent versus more frequent cannabis use, mixed-effects models used to for associations between cannabis use and outcomes.</td>
<td>Greater than 80% of MCP participants reduced their daily opioid doses. 40% of MCP enrollees ceased filling opioid prescription after 1.5 years into the MCP. MCP patients also reported increased quality of life and decreased pain levels.</td>
<td>Level IV evidence. Strength: study conducted over a long period of time (21 months). Weakness: Convenience sample from a medical cannabis program in New Mexico.</td>
</tr>
<tr>
<td>Campbell G et al. [7], Effect of cannabis use in people with chronic non-cancer pain prescribed opioids: findings from a 4-year prospective cohort study.</td>
<td>N=1514 Participants recruited from pharmacies across Australia with chronic non-cancer pain older than 18 years old, currently taking prescribed opioids for greater than 6 weeks.</td>
<td>Prospective Cohort Study</td>
<td>Ceased opioid prescriptions: no evidence from prescription monitoring program that an opioid was filled in the last three months of observation. Reduction in Prescribed Daily Opioid Dosage: average prescribed daily dose of IV morphine lower in the last three months of observation vs. the first three months. Percentage Point Change on Prescribed Daily Opioid Dosage: measures the difference between the average daily dose in the first and last three months of observation divided by the average daily dose in the first three months.</td>
<td>At 4-year follow-up, compared with people with no cannabis use, participants who used cannabis had a greater pain severity score. There was no evidence found that cannabis use decreased pain severity score or reduced opioid use.</td>
<td>Self-reported questionnaires and interviews over a 4 year period using the following scales: pain severity and interference (how pain affects sleep, daily living, working ability, and social interaction) subscales of the Brief Pain Inventory (BPI), 20 with higher scores indicating greater pain severity or interference (score range 0 to 10).</td>
<td>Level IV evidence. Strength: study conducted over a long period of time (4 years), and a large sample size (n=1514). Weakness: subjective data since it’s self-reported, the patients were using illicit cannabis and were not monitored by a medical provider over the duration of the study, and cannabis doses across the population were not consistent.</td>
<td>Level IV evidence.</td>
</tr>
</tbody>
</table>

*Level of evidence graded according to Melnyk BM et al. [21]. “Box 1.3: Rating system for the hierarchy of evidence for intervention/treatment questions

in the IRR. Table 1 includes an evaluation of the data collection for the IRR. The table includes all ten studies used to answer the research questions. The variables of the studies include the following: citation, sample/setting, major study variables and definitions, measurement of major variables, data analysis, study findings, level of evidence, and appraisal of worth.
addiction and worsening of psychiatric illness [23]. Relatively, another study revealed greater generalized anxiety disorder severity scores in patients who used cannabis compared to those with no cannabis use [7]. Perhaps, limiting the use of cannabis to those without psychiatric disorders would be helpful in these instances. Likewise, those at risk of cannabis use disorder or addiction have “poor working memory capacity and high trait impulsivity” [24]. Therefore, healthcare providers should limit cannabis use in this population.

Furthermore, in several studies, there was essentially a substitution of opioids with medical cannabis [25-28]. In these studies, cannabis use was associated with reductions in opioid doses or cessation of opioids. Conflicting evidence was established that illicit cannabis use did not have an opioid sparing effect [7]. Though, medical cannabis patients reported improvements after three months of treatment in clinical state and health-related measures, and notable decreases in prescription medication use, particularly opioids and benzodiazepines [29,30].

Lastly, a study in 2018 proved that pain intensity was significantly better in non-opioids than opioids over a twelve-month period (p=0.03) [10]. Therefore, treatment with opioids was not superior to other pain management alternatives in the treatment of chronic back pain or hip or knee pain related to osteoarthritis. However, pain alternatives such as acetaminophen and NSAID’s have adverse events such as liver and renal failure, respectively, with long-term use and high dosages.

The implications of practice include recommending medical cannabis to appropriate clients as an intervention for the management of chronic pain instead of opioids, in conjunction with legal use and medical supervision. If cannabis is substituted for opioids, prevention of opioid addiction and fatal overdoses will inevitably occur. Health care providers, including Nurse Practitioners, must stop overprescribing opioids because they are familiar or comfortable with that form of treatment, and choose safer alternatives such as cannabis. Thus, improvements in clinical outcomes can be achieved such as appropriately managed pain and reductions in opioid overdoses.

Limitations

Most of the studies mentioned a lack of randomized controlled trials due to cannabis’ schedule I status, which creates a barrier to randomly assign patients in RCT’s. Therefore, medical cannabis patients self-enrolled into a program to be included in the US study samples. Most studies were limited by small sample sizes, and in almost all of the systematic reviews there was variability of THC doses and short study durations. Likewise, there was lack of long-term clinical trials and the safety of cannabis among young and vulnerable populations [12]. A longitudinal study performed in Australia included the use of illicitly produced cannabis but failed to incorporate the guidance or supervision of a medical provider [7]. Additionally, cannabis doses were inconsistent across the study population.

There was also an inability to blind patients related to psychoactive effects of cannabis, which caused a few patients to drop out of studies. One review excluded patient diagnoses such as depression [22]. Other studies indicated limitations related to the inability to adjust for race/ethnicity, socioeconomic status, and medical/psychiatric diagnoses; lacked a comparison group, inability to determine the effective cannabis dose, low response rate, and lack of knowledge on the specific opioids being used; homogeneity of the group selected [16,26,27].

The restrictions of these studies are the support for the need for further research that can operate around legal barriers. Ultimately, most of the authors were unable to generalize the use of medical cannabis in relation to chronic non-cancer pain due to lack of supporting evidence. With such limitations, further comprehensive evidence is needed on the relationship between medical cannabis and its therapeutic outcome.

Conclusion

This IRR was supported by adequate evidence that medical cannabis is an effective treatment for chronic pain management and can be substituted for opioids. Although there are some negative adverse effects, they do not measure up to the harsh consequences of opioids and the amount of overdose deaths. However, adverse events of medical cannabis increase with higher potencies of THC. Most of the studies reviewed indicated the positive effects and efficacy of medical cannabis as an option or alternative to opioids in the management and treatment of chronic pain associated with neurological, musculoskeletal, non-cancer as well as cancer conditions. These studies, however, recommended further rigorous research to determine the effective cannabis dose and long-term feasibility. Medical cannabis also has the potential to prevent oversubscribing of opioids amidst the opioid epidemic in the US and Canada. If thorough research is performed, it may be able to reduce harmful opioid effects and prevent cannabis misuse.

References


24. Lopez-Vergara HI, Jackson KM, Mesheha LZ, Metrik J. Dysregulation as a correlate of cannabis use and problem use. Addict Behav. 2019;95:138-44.


